Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 166, Issue 2, 2001, Pages 1314-1319

  Hilliard, B ^a   Wilmen, A ^a   Seidel, C ^a   Liu, T S T ^a   Goke R ^a   Chen, Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CELL TRANSFORMATION; CONTROLLED STUDY; INFLAMMATORY CELL; LIGAND BINDING; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; T LYMPHOCYTE ACTIVATION;

EID: 0035863835     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.2.1314     Document Type: Article

References (47)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
3. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
4. Characterization of two receptors for TRAIL
5. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α
6. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
7. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
8. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
9. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
10. 2 ligand: A novel lethal weapon against malignant glioma?
11. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells
12. TRAIL death pathway expression and induction in thyroid follicular cells
13. Expression of TRAIL and its receptors in human brain tumors
14. 1FN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression
15. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor
16. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
17. TRAIL/Apo-2-ligand-induced apoptosis in human T cells
18. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
19. Safety and antitumor activity of recombinant soluble Apo2 ligand
20. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
21. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
22. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
23. Experimental autoimmune encephalomyelitis: Augmentation of demyelination by different myelin lipids
24. Mechanisms of recovery from experimental autoimmune encephalomyelitis: T cell deletion and immune deviation in myelin basic protein T cell receptor transgenic mice
25. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas
26. Overview of protein expression in Pichia pastoris
27. Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease
28. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra
29. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
30. Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor
31. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis
32. Clincial, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis
33. The Fas death factor
34. The lpr and gld genes in systemic autoimmunity: Life and death in the Fas lane
35. Fas and Fas ligand: lpr and gld mutations
36. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice
37. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
38. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system
39. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
40. The role of Fas in autoimmune diabetes
41. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction
42. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts
43. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice
44. Amelioration of collagen-induced arthritis by Fas (CD95)-ligand gene transfer
45. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice
46. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
47. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II